GENEVA, 2 October 2024—Responding to today’s announcement by Gilead on lenacapavir ... and have been agreed: collaborate, follow science, tackle inequalities, protect everyone’s rights, let ...
Fintel on MSN8h
Leerink Partners Upgrades Gilead Sciences (GILD)Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...
After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Fintel on MSN3d
Bernstein Initiates Coverage of Gilead Sciences (GILD) with Outperform RecommendationFintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...
AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American biopharmaceutical company with a market value of approximately $96bn, regarding a ...
Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...
The Joint United Nations Programme on HIV/AIDS (UNAIDS) welcomed US-based Gilead Science's announcement of voluntary licensing of its long acting HIV drug lenacapavir for generic production, and asked ...
US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income countries. The announcement ...
Gilead Sciences (GILD) closed the latest trading day at $83.79, indicating a -0.24% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.25%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback